Maternal immune activation (MIA) during pregnancy is recognized as an etiological risk factor for various psychiatric disorders, such as schizophrenia, major depressive disorder, and autism. Prenatal immune challenge may serve as a “disease primer” for alteration of the trajectory of fetal brain development that, in combination with other genetic and environmental factors, may ultimately result in the emergence of different psychiatric conditions. However, the association between MIA and an offspring’s chance of developing anxiety disorders is less clear. To evaluate the effect of MIA on offspring anxiety, a systematic review and meta-analysis of the preclinical literature was conducted. We performed a systematic search of the PubMed, Web of Science, PsycINFO, and Cochrane Library electronic databases using the PRISMA and World Health Organization (WHO) methodologies for systematic reviews. Studies that investigated whether MIA during pregnancy could cause anxiety symptoms in rodent offspring were included. Overall, the meta-analysis showed that MIA induced anxiety behavior in offspring. The studies provide strong evidence that prenatal immune activation impacts specific molecular targets and synapse formation and function and induces an imbalance in neurotransmission that could be related to the generation of anxiety in offspring. Future research should further explore the role of MIA in anxiety endophenotypes. According to this meta-analysis, MIA plays an important role in the pathophysiological mechanisms of anxiety disorders and is a promising therapeutic target.
Cancer-associated thrombosis is a major cause of morbidity and mortality in patients with cancer and is associated with a high risk of both recurrent venous thromboembolism (VTE) and bleeding. Although extended anticoagulation reduces the risk of recurrent VTE by more than 80%, full-dose therapy may increase bleeding complications, potentially offsetting its benefit in this population. Reduced-dose direct oral anticoagulants (DOACs) have therefore been proposed as a safer long-term treatment option. We conducted a systematic review and meta-analysis of randomized controlled trials comparing reduced-dose DOACs with standard-dose regimens for extended VTE treatment in cancer patients. Outcomes included recurrent VTE, major bleeding, clinically relevant nonmajor bleeding, all-cause mortality, and composite bleeding, with pooled odds ratios calculated using random-effects models. Five randomized trials involving 2709 patients were included. Recurrent VTE rates were comparable between reduced-dose and standard-dose DOACs. Reduced-dose therapy was associated with a significant reduction in clinically relevant nonmajor bleeding and composite bleeding. While major bleeding occurred less, the difference was not statistically significant. Overall, reduced-dose DOACs demonstrated similar efficacy in preventing recurrent VTE while offering an improved bleeding profile, supporting their potential role in long-term management of cancer-associated thrombosis, though larger prospective studies are needed to define optimal dosing strategies.
27 March 2026 in Journal of Gastrointestinal Cancer